Evidence map›Paper›PMID 36204033›Full record

ArticleCureus2022

The Impact of Inflammatory Bowel Disease on Mortality and Other Outcomes of Hospitalized Patients With Diabetic Ketoacidosis: An Observational Study of the United States National Inpatient Sample.

Mohammad Aldiabat, Yazan Aljabiri, Yassine Kilani, Mubarak H Yusuf, Mohannad H Al-Khateeb, Ali Horoub, Farukhuddin Farukhuddin, Ratib Mahfouz, Adham E Obeidat

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Mohammad AldiabatInternal Medicine/Geriatrics, NYU Langone Hospital, Mineola, USA.
Yazan AljabiriInternal Medicine, New York City Health and Hospitals Corporation (NYCHHC) Lincoln Medical Center, New York City, USA.
Yassine KilaniInternal Medicine, New York City Health and Hospitals Corporation (NYCHHC) Lincoln Medical Center, New York City, USA.
Mubarak H YusufInternal Medicine, New York City Health and Hospitals Corporation (NYCHHC) Lincoln Medical Center, New York City, USA.
Mohannad H Al-KhateebInternal Medicine, New York City Health and Hospitals Corporation (NYCHHC) Lincoln Medical Center, New York City, USA.
Ali HoroubInternal Medicine, New York City Health and Hospitals Corporation (NYCHHC) Lincoln Medical Center, New York City, USA.
Farukhuddin FarukhuddinInternal Medicine, New York City Health and Hospitals Corporation (NYCHHC) Lincoln Medical Center, New York City, USA.
Ratib MahfouzInternal Medicine, Kent Hospital/Brown University, Warwick, USA.
Adham E ObeidatHepatology, Rutgers University New Jersey Medical School, Newark, USA.
New York City Health and Hospitals Corporation · USKent Hospital · USRutgers, The State University of New Jersey · USWinthrop-University Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Recent studies have shown an increased risk of diabetes mellitus in patients with Inflammatory bowel disease. However, the impact of IBD on outcomes of patients with diabetic ketoacidosis remains unknown. Methods This is an observational analysis of the National Inpatient Sample Database. The authors identified patients with a diagnosis of diabetic ketoacidosis and inflammatory bowel diseases. Outcomes studied were differences in risk of mortality, in-hospital outcomes and healthcare resources utilization. Multivariate logistic analysis was performed and results were adjusted for patient and hospital characteristics and comorbidities. Results No significant difference in mortality was observed in the DKA-IBD group when compared to the DKA-only group (aOR 0.55, p = 0.560). Similarly, inflammatory bowel disease had no impact on risk of sepsis (aOR 1.06, p = 0.742), acute kidney injury (aOR 1.08, p = 0.389), acute coronary syndrome (aOR 0.70, p = 0.397), ischemic stroke (aOR 1.53, p = 0.094), acute respiratory failure (aOR 1.00, p = 0.987), invasive mechanical ventilation (aOR 0.54, p = 0.225), deep vein thrombosis (aOR 1.68, p = 0.275), pulmonary embolism (aOR 2.16, p = 0.279) or cardiac arrest (aOR 1.35, p = 0.672) in diabetic ketoacidosis patients. The study group had a significant increase in length of stay (adjusted mean difference 0.63, p = 0.002) and charge of care (adjusted mean difference 3,950$, p = 0.026). Conclusion Inflammatory bowel disease is not associated with risk difference in mortality or morbidity in admitted patients with diabetic ketoacidosis, however, it does contribute to increased healthcare resources utilization.

Indexed as

crohn’s diseasediabetes mellitusdiabetic ketoacidosisinflammatory bowel diseasesulcerative colitis

Identifiers

PMID36204033
PMCPMC9527063
OpenAlexW4294300961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.